Opendata, web and dolomites

ARTimmune SIGNED

Programmable ARTificial immune systems to fight cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ARTimmune project word cloud

Explore the words cloud of the ARTimmune project. It provides you a very rough idea of what is the project "ARTimmune" about.

scaffolds    programming    immunomodulating    function    direct    accomplished    destruction    vaccinated    act    transcriptomics    cell    injectable    porosity    programmable    moving    revolutionize    hypothesize    bursts    local    immunological    vivo    synthetic    systemic    mixed    patients    toxic    roadblocks    notwithstanding    node    fine    advantage    toxicity    blueprint    tolerable    single    tumour    cytotoxic    follow    immune    decorated    powerhouses    stage    immunotherapies    fundamental    intelligent    obstacles    centre    sponge    ln    branched    immunotherapy    immunosuppression    architecture    pressing    proteolytic    radically    injected    activation    polymeric    clusters    dose    illustrate    tuning    communication    instruct    immunomodulators    generate    maximal    character    tools    mimic    extend    cancer    overcome    structures    molecules    infiltration    niches    entered    modality    innovative    vicinity    revolutionary    artimmune    span    successful    lymph    cells    chemical    life    locally    powerful    treatment   

Project "ARTimmune" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2024-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 2˙500˙000.00

Map

 Project objective

Immunotherapy has entered centre stage as a novel treatment modality for cancer. Notwithstanding this major step forward, toxicity and immunosuppression remain major obstacles, and illustrate the pressing need for more powerful and specific immunotherapies against cancer. To overcome these roadblocks, in ARTimmune, I propose to follow a radically different approach by developing local rather than systemic immunotherapies. Taking advantage of the architecture of a lymph node (LN), I aim to design fully synthetic immune niches to locally instruct immune cell function. I hypothesize that programmable synthetic immune niches, when injected next to a tumour, will act as local powerhouses to generate bursts of cytotoxic T cells for tumour destruction, without toxic side effects. Single cell transcriptomics on LN, obtained from patients that are vaccinated against cancer, will provide unique insight in communication within immune cell clusters and provide a blueprint for the intelligent design of synthetic immune niches. Chemical tools will be used to build branched polymeric structures decorated with immunomodulating molecules to mimic LN architecture. These will be injected, mixed with sponge-like scaffolds to provide porosity needed for immune cell infiltration. Programming of immune cell function will be accomplished by in vivo targeting- and proteolytic activation- of immunomodulators for fine-tuning, and to extend the life span of these local powerhouses. The innovative character of ARTimmune comes from: 1) novel fundamental immunological insight in complex communication within LN cell clusters, 2) a revolutionary new approach in immunotherapy, by the development of 3) injectable- and 4) programmable- synthetic immune niches by state-of-the-art chemical technology. When successful, it will revolutionize cancer immunotherapy, moving from maximal tolerable dose systemic treatment with significant toxicity to local low dose treatment in the direct vicinity of a tumour

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARTIMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ARTIMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

ORGANITRA (2019)

Transport of phosphorylated compounds across lipid bilayers by supramolecular receptors

Read More  

OSIRIS (2020)

Automatic measurement of speech understanding using EEG

Read More